Ke Su

Ke Su


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BYBo Yi
Bo Yi
KSKe Su
Ke Su
YCYu-Li Cai
Yu-Li Cai
XCXiao-Ling Chen
Xiao-Ling Chen
YBYan Bao
Yan Bao
ZWZhongyuan Wen
Zhongyuan Wen

2 November 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QGQi Gao
Qi Gao
YCYuan Cai
Yuan Cai
YZYuanbo Zhang
Yuanbo Zhang
XSXianci Song
Xianci Song
JDJunwu Dong
Junwu Dong
KSKe Su
Ke Su
Objective: We aimed to investigate the association of combined finerenone and tripterygium glycosides (TG) therapy with proteinuria reduction in patients with diabetic kidney disease (DKD). Methods: This retrospective cohort study included patients with DKD and an estimated glomerular filtration rate (eGFR) of 15 to 0.05). However, the incidences of hyperkalemia and liver and kidney-related adverse events were also comparable between the groups (all P > 0.05). Conclusion: In patients with DKD and an eGFR of 15 to <60 mL/min/1.73 m 2 , combination therapy with TG and finerenone was associated with a greater reduction in UACR than finerenone alone, without a significant increase in the risk of the assessed adverse events. Further evaluation in prospective randomized trials is warranted.